Tearing Up: New and Emerging Therapy With Tear Stimulation for Dry Eye Disease (CME Monograph)
Activity Description and Purpose
Increased understanding of the pathophysiology of dry eye disease (DED) over the past few decades has led to advances in its diagnosis and to new treatments, with a particular focus on medications for controlling inflammation. Dissatisfaction among both patients and physicians with anti-inflammatory modalities for managing DED, however, suggests the need for additional treatments. New and emerging therapies for DED are aimed at increasing natural tear production. In this educational activity, experts in DED present a review of natural tear production and its importance for ocular surface health, describe new and emerging tear stimulation treatments for DED, including data from pivotal trials, and share insights on therapeutic decision making based on real-world situations of patients with DED.
This educational activity is intended for ophthalmologists.
After completing this activity, participants will be better able to:
- Review the benefits of natural tear production for ocular surface health
- Describe the mechanisms of actions of new and emerging tear stimulation treatments for dry eye disease
- Review the latest clinical trial data for new and emerging tear stimulation treatments for dry eye disease
- Identify patients who would be good candidates for tear stimulation treatments
Michael B. Raizman, MD (Chair)
Ophthalmic Consultants of Boston
Associate Professor of Ophthalmology
Director, Corneal Fellowship Training Program
Director, Cornea and Anterior Segment Services
Tufts University School of Medicine
Anat Galor, MD, MSPH
Professor of Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Staff Physician, Miami Veterans Affairs Medical Center
David Wirta, MD
Principal Investigator and Medical Director
Eye Research Foundation, Inc
Newport Beach, California
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Anat Galor, MD, MSPH, is a consultant for Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, and Tarsus Pharmaceuticals, Inc.
Michael B. Raizman, MD, is a consultant for Alcon, Eyevance, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, Palatin Technologies, Inc, and Sun Pharmaceutical Industries, Inc.
David Wirta, MD, is a contracted researcher for Oyster Point Pharma, Inc.
This activity was peer reviewed. The peer reviewer has no relevant financial relationships.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Oyster Point Pharma, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC; Oyster Point Pharma, Inc; EyeNet; or the American Academy of Ophthalmology.
This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 250
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation